Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSV-allo
- Development stage
- Phase 2
- Lead developer
- Hospital Universitario Puerta de Hierro
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Intravitreal
01
Overview
**MSV-allo** is an investigational, allogeneic bone marrow-derived mesenchymal stromal cell therapy developed in Spain for inflammatory, autoimmune, musculoskeletal, pulmonary, and ophthalmic indications. The product contains expanded donor-derived mesenchymal stromal cells administered as a cell suspension, with route tailored to the indication, including intravenous infusion, intra-articular injection, and intravitreal injection. Its therapeutic rationale is the broad paracrine immunomodulatory, anti-inflammatory, tissue-repair, and potentially neuroprotective activity of mesenchymal stromal cells rather than inhibition or activation of one defined molecular target. MSV-allo has been studied in knee osteoarthritis, severe COVID-19 pneumonia with acute respiratory failure, lupus nephritis, and acute non-arteritic anterior ischemic optic neuropathy. A lupus nephritis study is listed in CTIS as an ongoing integrated Phase II/III trial. ([itrt.es](https://www.itrt.es/en/knee-arthritis-treated-mesenchymal-stem-cells/))
- Other names
- MSV alloMSV-ALLOMSV-allo®
Beyond the preview
Go deeper on MSV-allo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSV-allo.